Benu BioPharma

Benu BioPharma is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer. The company's primary strategy involves targeting the DNA damage response (DDR) pathway to enhance the efficacy of existing treatments and overcome resistance in solid tumors. Its lead candidate, BBP-390, is a potent and selective inhibitor of Checkpoint kinase 1 (CHK1) currently being evaluated in clinical trials. Benu BioPharma aims to leverage its expertise in medicinal chemistry and oncology to build a robust pipeline of precision medicines. The company was founded by industry veterans with extensive experience in oncology drug discovery and development. By focusing on specific genetic vulnerabilities in cancer cells, Benu BioPharma seeks to provide more effective and less toxic treatment options for patients.